Mylan tops profit estimates as newer drugs spur North America growth

(Reuters) - Mylan NV beat Wall Street estimates for third-quarter profit on Tuesday, as its biggest market, North America, benefited from launches of lung disease therapies Wixela and Yupelri.The generic drugmaker's shares, down nearly 28% this year, were trading up 2% at $20 before the bell.The North America unit, which accounts for over a third of Mylan's total revenue, has been grappling with intense competition, falling drug prices and expenses related to fixing issues at its Morgantown..